Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US34962G2084
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG001J2N4H0
FBRX

Forte Biosciences, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Forte Biosciences, Inc.
ISIN
US34962G2084
TICKER
FBRX
MIC
XNAS
REUTERS
FBRX.OQ
BLOOMBERG
FBRX US
Tue, 04.08.2026       Forte Biosciences

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basi...
Tue, 28.07.2026       Forte Biosciences

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte...
Mon, 27.07.2026       Forte Biosciences

NEW YORK, July 27, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in...
Mon, 27.07.2026       Forte Biosciences

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash.Halper Sadeh encourages Forte shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersade...
Mon, 27.07.2026       Forte Biosciences

MILWAUKEE, July 27, 2026 /PRNewswire/ -- Ademi LLP is investigating Forte (Nasdaq: FBRX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with argenx. Click here to learn how to join our investigation and obtain additional info...
Mon, 27.07.2026       Forte Biosciences

argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc.  (Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion. FB102,...
Thu, 09.07.2026       Forte Biosciences

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p-value =...
Wed, 28.08.2024       Forte Biosciences

Instrument ID [20756362] (37T - US34962G2084) suspended...
Tue, 27.08.2024       Forte Biosciences

Das Instrument 37T US34962G2084 FORTE BIOSCIENCES INC. EQUITY hat seinen ersten Handelstag am 28.08.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N The instrument 37T US34962G2084 FORTE BIOSCIENCES INC. EQUITY has its first trading date on 28.08.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...